September 17, 2015
Boston, MA
There’s no question about it, patent practice in the pharmaceutical and biotechnology fields is becoming even more complex. We have seen many changes over the past few months in the area of patent protection in the life sciences, such as the first implementation (or lack thereof) of the Biologics Price Competition and Innovation Act (BPCIA) provisions, an increased number of IPRs involving pharmaceutical and biotech patents, the Federal Circuit’s latest word on joint infringement, changes in the Section 101 subject matter eligibility landscape, and the expansion of the doctrine of obviousness type double patenting and the consequent effect on patent term adjustment.
Please join us for an interactive discussion including:
Due to space limitations, please register early.
Jonathan R. Davies, Ph.D.
Jeffrey M. Jacobstein
Howard W. Levine
Alissa K. Lipton
Leslie A. McDonell
Sanya Sukduang
Nathaniel S. Edwards, Ph.D., IP Counsel, Biogen
Thursday, September 17, 2015
8:30 - 9:15 a.m. – Registration and Breakfast
9:15 - 11:45 a.m. – Workshop
11:45 a.m. - 12:30 p.m. – Working Lunch
12:30 - 3:45 p.m. – Workshop
Finnegan
Two Seaport Lane
Boston, MA 02210
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Conference
Boston Intellectual Property Law Association 4th Annual Symposium
April 10-11, 2024
Boston
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.